Update in the Management of Macular Edema Following Retinal Vein Occlusions

Mariana R. Thorell, Raquel Goldhardt

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Retinal vein occlusion (RVO) is a common retinal vascular disease classified according to the anatomical location of the occlusion in central (CRVO) or branch (BRVO) retinal vein occlusion. RVO is an important cause of visual loss worldwide and frequently results in visual impairment and ocular complications. Major causes of vision loss in BRVO and CRVO include macular edema (ME), capillary nonperfusion, and neovascularization, causing glaucoma, vitreous hemorrhage, and/or tractional retinal detachment (The Branch Vein Occlusion Study Group in Am J Ophthalmol 98:271–82, 1984). Macular edema is the leading cause of decreased central visual acuity in RVO (Gass in Stereoscopic atlas of macular diseases: diagnosis and treatment, 1997). Recently, there was a paradigm shift in the treatment of ME due to RVO with the advent of new pharmacotherapy treatment strategies and combination therapies. This paper reviews the current thinking and discusses the evidence behind the emerging treatment options for ME following RVO, including laser photocoagulation, intravitreal anti-vascular endothelial growth factor (VEGF), intravitreal corticosteroid-based pharmacotherapies, and surgical management.

Original languageEnglish (US)
Pages (from-to)38-47
Number of pages10
JournalCurrent Ophthalmology Reports
Issue number1
StatePublished - Mar 1 2016


  • Intravitreal injections
  • Macular edema
  • Retinal vein occlusion
  • Steroids
  • Vascular endothelial growth factors

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Update in the Management of Macular Edema Following Retinal Vein Occlusions'. Together they form a unique fingerprint.

Cite this